ブルセラ症治療のグローバル市場2023年:経口式、注射式

【英語タイトル】Global Brucellosis Treatment Market Research Report 2023

QYResearchが出版した調査資料(QYR23MA7434)・商品コード:QYR23MA7434
・発行会社(調査会社):QYResearch
・発行日:2023年3月
・ページ数:88
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,900 ⇒換算¥429,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD4,350 ⇒換算¥643,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,800 ⇒換算¥858,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

本調査レポートは世界のブルセラ症治療市場について調査・分析し、世界のブルセラ症治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析(経口式、注射式)、用途別セグメント分析(病院、薬局、その他)、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer Inc.、Bayer、Huvepharma、OraPharma,Inc.、Merck & Co.Inc.、RempexPharmaceuticals,Inc.、ZeotisInc.、BoehringerIngelheim International GmbH.、Elanco、Virabc Inc.などが含まれています。世界のブルセラ症治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。COVID-19とロシア・ウクライナ戦争の影響は、ブルセラ症治療市場規模を推定する際に考慮しました。

・ブルセラ症治療市場の概要
- ブルセラ症治療のタイプ別セグメント
- 世界のブルセラ症治療市場規模:タイプ別分析(経口式、注射式)
- ブルセラ症治療の用途別セグメント
- 世界のブルセラ症治療市場規模:用途別分析(病院、薬局、その他)
- 世界のブルセラ症治療市場規模予測(2018年-2029年)

・ブルセラ症治療市場の成長トレンド
- ブルセラ症治療の地域別市場規模(2018年-2029年)
- ブルセラ症治療市場ダイナミクス
- ブルセラ症治療の業界動向
- ブルセラ症治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M&A動向

・タイプ別セグメント:経口式、注射式
- 世界のブルセラ症治療のタイプ別市場規模(2018年-2023年)
- 世界のブルセラ症治療のタイプ別市場規模(2024年-2029年)

・用途別セグメント:病院、薬局、その他
- 世界のブルセラ症治療の用途別市場規模(2018年-2023年)
- 世界のブルセラ症治療の用途別市場規模(2024年-2029年)

・ブルセラ症治療の地域別市場規模
- 北米のブルセラ症治療市場規模(2018年-2029年)
- アメリカのブルセラ症治療市場規模(2018年-2029年)
- ヨーロッパのブルセラ症治療市場規模(2018年-2029年)
- アジア太平洋のブルセラ症治療市場規模(2018年-2029年)
- 中国のブルセラ症治療市場規模(2018年-2029年)
- 日本のブルセラ症治療市場規模(2018年-2029年)
- 韓国のブルセラ症治療市場規模(2018年-2029年)
- インドのブルセラ症治療市場規模(2018年-2029年)
- オーストラリアのブルセラ症治療市場規模(2018年-2029年)
- 中南米のブルセラ症治療市場規模(2018年-2029年)
- 中東・アフリカのブルセラ症治療市場規模(2018年-2029年)

・主要企業のプロファイル:企業情報、事業概要、売上、動向
Pfizer Inc.、Bayer、Huvepharma、OraPharma,Inc.、Merck & Co.Inc.、RempexPharmaceuticals,Inc.、ZeotisInc.、BoehringerIngelheim International GmbH.、Elanco、Virabc Inc.

・アナリストの観点/結論

・調査方法とデータソース

Highlights
The global Brucellosis Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Brucellosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Brucellosis Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Brucellosis Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Brucellosis Treatment include Pfizer Inc., Bayer, Huvepharma, OraPharma,Inc., Merck & Co.Inc., RempexPharmaceuticals,Inc., ZeotisInc., BoehringerIngelheim International GmbH. and Elanco, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Brucellosis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Brucellosis Treatment.
The Brucellosis Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Brucellosis Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Brucellosis Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer Inc.
Bayer
Huvepharma
OraPharma,Inc.
Merck & Co.Inc.
RempexPharmaceuticals,Inc.
ZeotisInc.
BoehringerIngelheim International GmbH.
Elanco
Virabc Inc.
Segment by Type
Oral
Injection
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Brucellosis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Brucellosis Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Brucellosis Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Brucellosis Treatment Market Perspective (2018-2029)
2.2 Brucellosis Treatment Growth Trends by Region
2.2.1 Global Brucellosis Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Brucellosis Treatment Historic Market Size by Region (2018-2023)
2.2.3 Brucellosis Treatment Forecasted Market Size by Region (2024-2029)
2.3 Brucellosis Treatment Market Dynamics
2.3.1 Brucellosis Treatment Industry Trends
2.3.2 Brucellosis Treatment Market Drivers
2.3.3 Brucellosis Treatment Market Challenges
2.3.4 Brucellosis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Brucellosis Treatment Players by Revenue
3.1.1 Global Top Brucellosis Treatment Players by Revenue (2018-2023)
3.1.2 Global Brucellosis Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Brucellosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Brucellosis Treatment Revenue
3.4 Global Brucellosis Treatment Market Concentration Ratio
3.4.1 Global Brucellosis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Brucellosis Treatment Revenue in 2022
3.5 Brucellosis Treatment Key Players Head office and Area Served
3.6 Key Players Brucellosis Treatment Product Solution and Service
3.7 Date of Enter into Brucellosis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Brucellosis Treatment Breakdown Data by Type
4.1 Global Brucellosis Treatment Historic Market Size by Type (2018-2023)
4.2 Global Brucellosis Treatment Forecasted Market Size by Type (2024-2029)
5 Brucellosis Treatment Breakdown Data by Application
5.1 Global Brucellosis Treatment Historic Market Size by Application (2018-2023)
5.2 Global Brucellosis Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Brucellosis Treatment Market Size (2018-2029)
6.2 North America Brucellosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Brucellosis Treatment Market Size by Country (2018-2023)
6.4 North America Brucellosis Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Brucellosis Treatment Market Size (2018-2029)
7.2 Europe Brucellosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Brucellosis Treatment Market Size by Country (2018-2023)
7.4 Europe Brucellosis Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Brucellosis Treatment Market Size (2018-2029)
8.2 Asia-Pacific Brucellosis Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Brucellosis Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Brucellosis Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Brucellosis Treatment Market Size (2018-2029)
9.2 Latin America Brucellosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Brucellosis Treatment Market Size by Country (2018-2023)
9.4 Latin America Brucellosis Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Brucellosis Treatment Market Size (2018-2029)
10.2 Middle East & Africa Brucellosis Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Brucellosis Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Brucellosis Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Brucellosis Treatment Introduction
11.1.4 Pfizer Inc. Revenue in Brucellosis Treatment Business (2018-2023)
11.1.5 Pfizer Inc. Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Brucellosis Treatment Introduction
11.2.4 Bayer Revenue in Brucellosis Treatment Business (2018-2023)
11.2.5 Bayer Recent Development
11.3 Huvepharma
11.3.1 Huvepharma Company Detail
11.3.2 Huvepharma Business Overview
11.3.3 Huvepharma Brucellosis Treatment Introduction
11.3.4 Huvepharma Revenue in Brucellosis Treatment Business (2018-2023)
11.3.5 Huvepharma Recent Development
11.4 OraPharma,Inc.
11.4.1 OraPharma,Inc. Company Detail
11.4.2 OraPharma,Inc. Business Overview
11.4.3 OraPharma,Inc. Brucellosis Treatment Introduction
11.4.4 OraPharma,Inc. Revenue in Brucellosis Treatment Business (2018-2023)
11.4.5 OraPharma,Inc. Recent Development
11.5 Merck & Co.Inc.
11.5.1 Merck & Co.Inc. Company Detail
11.5.2 Merck & Co.Inc. Business Overview
11.5.3 Merck & Co.Inc. Brucellosis Treatment Introduction
11.5.4 Merck & Co.Inc. Revenue in Brucellosis Treatment Business (2018-2023)
11.5.5 Merck & Co.Inc. Recent Development
11.6 RempexPharmaceuticals,Inc.
11.6.1 RempexPharmaceuticals,Inc. Company Detail
11.6.2 RempexPharmaceuticals,Inc. Business Overview
11.6.3 RempexPharmaceuticals,Inc. Brucellosis Treatment Introduction
11.6.4 RempexPharmaceuticals,Inc. Revenue in Brucellosis Treatment Business (2018-2023)
11.6.5 RempexPharmaceuticals,Inc. Recent Development
11.7 ZeotisInc.
11.7.1 ZeotisInc. Company Detail
11.7.2 ZeotisInc. Business Overview
11.7.3 ZeotisInc. Brucellosis Treatment Introduction
11.7.4 ZeotisInc. Revenue in Brucellosis Treatment Business (2018-2023)
11.7.5 ZeotisInc. Recent Development
11.8 BoehringerIngelheim International GmbH.
11.8.1 BoehringerIngelheim International GmbH. Company Detail
11.8.2 BoehringerIngelheim International GmbH. Business Overview
11.8.3 BoehringerIngelheim International GmbH. Brucellosis Treatment Introduction
11.8.4 BoehringerIngelheim International GmbH. Revenue in Brucellosis Treatment Business (2018-2023)
11.8.5 BoehringerIngelheim International GmbH. Recent Development
11.9 Elanco
11.9.1 Elanco Company Detail
11.9.2 Elanco Business Overview
11.9.3 Elanco Brucellosis Treatment Introduction
11.9.4 Elanco Revenue in Brucellosis Treatment Business (2018-2023)
11.9.5 Elanco Recent Development
11.10 Virabc Inc.
11.10.1 Virabc Inc. Company Detail
11.10.2 Virabc Inc. Business Overview
11.10.3 Virabc Inc. Brucellosis Treatment Introduction
11.10.4 Virabc Inc. Revenue in Brucellosis Treatment Business (2018-2023)
11.10.5 Virabc Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



★調査レポート[ブルセラ症治療のグローバル市場2023年:経口式、注射式] (コード:QYR23MA7434)販売に関する免責事項を必ずご確認ください。
★調査レポート[ブルセラ症治療のグローバル市場2023年:経口式、注射式]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆